2024-09-27 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis

**Company Overview:** Amgen Inc. is a leading biotechnology company focused on developing and manufacturing innovative medicines for serious illnesses.

**1. Performance Comparison:**

* **Cumulative Return:** 75.32%
* **S&P 500 (VOO) Cumulative Return:** 133.29%
* **Difference:** -57.97% 
* **Relative Divergence:** 28.15% (This means AMGN has underperformed S&P 500, but its relative performance is better than 28.15% of its historical performance against S&P 500)

**2. Recent Price Movement:**

* **Closing Price:** $312.86
* **5-day Moving Average:** $331.01
* **20-day Moving Average:** $330.15
* **60-day Moving Average:** $327.69 

**3. Technical Indicators:**

* **RSI:** 38.86 (Below 50, indicating potential oversold conditions)
* **PPO:** -0.32 (Negative, suggesting a potential downtrend)
* **Delta_Previous_Relative_Divergence:** -11.63 (Negative, suggesting a short-term downward trend)
* **Expected Return:** 0.0% (Maximum estimated 5-year expected return on investment)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | $8.39 B |
| 2024-05-03 | -0.21 | $7.45 B |
| 2023-10-31 | 3.23 | $6.90 B |
| 2023-08-04 | 2.58 | $6.99 B |
| 2024-08-07 | 2.58 | $6.99 B |

* **Most Recent Earnings:** The most recent earnings report (2024-08-07) showed EPS of $1.39, exceeding analysts' estimates of $1.14. Revenue was also higher than anticipated, at $8.39B compared to the estimated $8.19B. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** Amgen continues to be a leader in the biotechnology sector, with strong revenue growth and a robust pipeline of new drugs. However, the company faces challenges from generic competition and the potential for new regulations.
* **Analyst Opinions:** Analysts generally hold a bullish outlook on AMGN, with many rating it as a "Buy" or "Strong Buy." The consensus price target is above the current market price, indicating potential upside.
* **Performance Highlights:** AMGN's recent stock performance has been mixed, with a slight downtrend in recent months. Despite this, the company has shown strong fundamentals and a solid track record of innovation, making it an attractive investment for long-term investors.

**6. Comprehensive Analysis:**

* AMGN has shown steady revenue growth and strong earnings in recent quarters. The company is positioned for continued growth in the biotechnology sector, with a robust pipeline of new products. 
* However, AMGN faces competition from generic drug manufacturers and potential regulatory challenges. 
* Technical indicators suggest a potential downtrend in the short-term, with RSI and PPO suggesting an oversold condition. 
* Overall, AMGN remains an attractive investment for long-term investors seeking exposure to the biotechnology sector, but short-term volatility may continue. 

**7. Report Conclusion:**

Amgen Inc. (AMGN) is a solid company with a strong track record of innovation in the biotechnology sector. While the recent stock performance has been mixed and there are some short-term headwinds, the company's long-term fundamentals remain strong. Investors who are looking for exposure to the biotechnology sector should consider adding AMGN to their portfolios. However, short-term investors should proceed with caution as the stock may be subject to continued volatility. 
